Novel candidate key drivers in the integrative network of genes, micrornas, methylations, and copy number variations in squamous cell lung carcinoma

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Huang, Tao ^a,b   Yang, Jing ^b   Cai, Yu Dong ^a  

^a SHANGHAI UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARF GAP WITH GTPASE DOMAIN ANKYRIN REPEAT AND PH DOMAIN 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HOMEOBOX D3 PROTEIN; HOMEODOMAIN PROTEIN; MICRORNA; MICRORNA 31; MICRORNA LET 7A; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; UNCLASSIFIED DRUG; MESSENGER RNA;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; GENE EXPRESSION; HUMAN; OVERALL SURVIVAL; SQUAMOUS CELL LUNG CARCINOMA; TUMOR GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; LUNG TUMOR; PROCEDURES; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; LUNG NEOPLASMS; MICRORNAS; RNA, MESSENGER;

EID: 84924529862     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/358125     Document Type: Article

References (256)

1. S. Ramalingam, K. Pawlish, S. Gadgeel, R. Demers, and G. P. Kalemkerian, "Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database," Journal of Clinical Oncology, Vol. 16, no. 2, pp. 651-657, 1998.
2. Y. E. Miller, "Pathogenesis of lung cancer: 100 Year report," American Journal of Respiratory Cell and Molecular Biology, Vol. 33, no. 3, pp. 216-223, 2005.
3. W. D. Travis, "Pathology of lung cancer," Clinics in Chest Medicine, Vol. 32, no. 4, pp. 669-692, 2011.
4. K. B. Sriram, J. E. Larsen, S. M. Savarimuthu Francis et al., "Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma," PLoS ONE, Vol. 7, no. 2, Article ID e30398, 2012.
5. J. W. Son, K. J. Jeong, W.-S. Jean et al., "Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients," Cancer Letters, Vol. 311, no. 1, pp. 29-37, 2011.
6. I. I. Wistuba, C. Behrens, S. Milchgrub et al., "Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma," Oncogene, Vol. 18, no. 3, pp. 643-650, 1999.
7. I. I. Wistuba, C. Behrens, A. K. Virmani et al., "High resolution chromosome 3p allelotyping of human lung cancer and pre-neoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints," Cancer Research, Vol. 60, no. 7, pp. 1949-1960, 2000.
8. A. Drilon, N. Rekhtman, M. Ladanyi, and P. Paik, "Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy," The Lancet Oncology, Vol. 13, no. 10, pp. e418-e426, 2012.
9. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr. et al., "Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis," Journal of Clinical Oncology, Vol. 21, no. 20, pp. 3798-3807, 2003.
10. S. Dacic, M. Flanagan, K. Cieply et al., "Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma," American Journal of Clinical Pathology, Vol. 125, no. 6, pp. 860-865, 2006.
11. A. J. Ekstrand, N. Sugawa, C. D. James, and V. P. Collins, "Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails," Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, no. 10, pp. 4309-4313, 1992.
12. H. Ji, X. Zhao, Y. Yuza et al., "Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors," Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, no. 20, pp. 7817-7822, 2006.
13. R. S. Heist, L. V. Sequist, and J. A. Engelman, "Genetic changes in squamous cell lung cancer: a review," Journal of Thoracic Oncology, Vol. 7, no. 5, pp. 924-933, 2012.
14. A. E. Karnoub and R. A. Weinberg, "Ras oncogenes: split personalities," Nature Reviews Molecular Cell Biology, Vol. 9, no. 7, pp. 517-531, 2008.
15. Y. Sowa and T. Sakai, "Ras/Raf/MEK/ERK cascade," Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol. 70, supplement 8, pp. 63-66, 2012.
16. J. L. Bos, "Ras oncogenes in human cancer: a review," Cancer Research, Vol. 49, no. 17, pp. 4682-4689, 1989.
17. P. M. K. Westcott and M. D. To, "The genetics and biology of KRAS in lung cancer," Chinese Journal of Cancer, Vol. 32, no. 2, pp. 63-70, 2013.
18. R. Seger and E. G. Krebs, "The MAPK signaling cascade," The FASEB Jour nal, Vol. 9, no. 9, pp. 726-735, 1995.
19. Y. Suzuki, M. Orita, M. Shiraishi, K. Hayashi, and T. Sekiya, "Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products," Oncogene, Vol. 5, no. 7, pp. 1037-1043, 1990.
20. T. Mitsudomi, J. Viallet, J. L. Mulshine, R. I. Linnoila, J. D. Minna, and A. F. Gazdar, "Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines," Oncogene, Vol. 6, no. 8, pp. 1353-1362, 1991.
21. J. A. Engelman, J. Luo, and L. C. Cantley, "The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism," Nature Reviews Genetics, Vol. 7, no. 8, pp. 606-619, 2006.
22. H. Yamamoto, H. Shigematsu, M. Nomura et al., "PIK3CA mutations and copy number gains in human lung cancers," Cancer Research, Vol. 68, no. 17, pp. 6913-6921, 2008.
23. O. Kawano, H. Sasaki, K. Okuda et al., "PIK3CA gene amplification in Japanese non-small cell lung cancer," Lung Cancer, Vol. 58, no. 1, pp. 159-160, 2007.
24. Y. Samuels, Z. Wang, A. Bardelli et al., "High frequency of mutations of the PIK3CA gene in human cancers," Science, Vol. 304, article 554, 2004.
25. O. Kawano, H. Sasaki, K. Endo et al., "PIK3CA mutation status in Japanese lung cancer patients," Lung Cancer, Vol. 54, no. 2, pp. 209-215, 2006.
26. I. Vivanco and C. L. Sawyers, "The phosphatidylinositol 3-kinase-AKT pathway in human cancer," Nature Reviews Cancer, Vol. 2, no. 7, pp. 489-501, 2002.
27. D. Malanga, M. Scrima, C. de Marco et al., "Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung," Cell Cycle, Vol. 7, no. 5, pp. 665-669, 2008.
28. J. Weiss, M. L. Sos, D. Seidel et al., "Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer," Science Translational Medicine, Vol. 2, no. 62, Article ID 62ra93, 2010.
29. I. Mason, "Initiation to end point: the multiple roles of fibroblast growth factors in neural development," Nature Reviews Neuroscience, Vol. 8, no. 8, pp. 583-596, 2007.
30. R. Dziadziuszko, D. T. Merrick, S. E. Witta et al., "Insulinlike growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression," Journal of Clinical Oncology, Vol. 28, no. 13, pp. 2174-2180, 2010.
31. F. Cappuzzo, G. Tallini, G. Finocchiaro et al., "Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients," Annals of Oncology, Vol. 21, no. 3, pp. 562-567, 2009.
32. A. Gualberto, M. Dolled-Filhart, M. Gustavson et al., "Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition," Clinical Cancer Research, Vol. 16, no. 18, pp. 4654-4665, 2010.
33. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization of squamous cell lung cancers," Nature, Vol. 489, no. 7417, pp. 519-525, 2012.
34. E. R. Zabarovsky, M. I. Lerman, and J. D. Minna, "Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers," Oncogene, Vol. 21, no. 45, pp. 6915-6935, 2002.
35. M. Rooney, S. Devarakonda, and R. Govindana, "Genomics of squamous cell lung cancer," Oncologist, Vol. 18, no. 6, pp. 707-716, 2013.
36. C. H. de Moor, H. Meijer, and S. Lissenden, "Mechanisms of translational control by the 3' UTR in development and differentiation," Seminars in Cell and Developmental Biology, Vol. 16, no. 1, pp. 49-58, 2005.
37. E. C. Lai, "Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation," Nature Genetics, Vol. 30, no. 4, pp. 363-364, 2002.
38. H. Robins and W. H. Press, "Human microRNAs target a functionally distinct population of genes with AT-rich 3' UTRs," Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, no. 43, pp. 15557-15562, 2005.
39. A. Stark, J. Brennecke, N. Bushati, R. B. Russell, and S. M. Cohen, "Animal microRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution," Cell, Vol. 123, no. 6, pp. 1133-1146, 2005.
40. M. Sun, L. D. Hurst, G. G. Carmichael, and J. Chen, "Evidence for a preferential targeting of 3'-UTRs by cis-encoded natural antisense transcripts," Nucleic Acids Research, Vol. 33, no. 17, pp. 5533-5543, 2005.
41. W. C. S. Cho, "MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy," International Journal of Biochemistry and Cell Biology, Vol. 42, no. 8, pp. 1273-1281, 2010.
42. L. He, X. He, S. W. Lowe, and G. J. Hannon, "MicroRNAs join the p53 network - another piece in the tumour-suppression puzzle," Nature Reviews Cancer, Vol. 7, no. 11, pp. 819-822, 2007.
43. W. C. S. Cho, "OncomiRs: the discovery and progress of microRNAs in cancers," Molecular Cancer, Vol. 6, article 60, 2007.
44. H.-W. Hwang and J. T. Mendell, "MicroRNAs in cell proliferation, cell death, and tumorigenesis," British Journal of Cancer, Vol. 94, no. 6, pp. 776-780, 2006.
45. A. Esquela-Kerscher and F. J. Slack, "Oncomirs - microRNAs with a role in cancer," Nature Reviews Cancer, Vol. 6, no. 4, pp. 259-269, 2006.
46. E. C. Lai, P. Tomancak, R. W. Williams, and G. M. Rubin, "Computational identification of Drosophila microRNA genes," Genome Biology, Vol. 4, no. 7, article R42, 2003.
47. B. J. Reinhart, F. J. Slack, M. Basson et al., "The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans," Nature, Vol. 403, no. 6772, pp. 901-906, 2000.
48. J. Takamizawa, H. Konishi, K. Yanagisawa et al., "Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival," Cancer Research, Vol. 64, no. 11, pp. 3753-3756, 2004.
49. S. M. Johnson, H. Grosshans, J. Shingara et al., "RAS is regulated by the let-7 microRNA family," Cell, Vol. 120, no. 5, pp. 635-647, 2005.
50. C. Mayr, M. T. Hemann, and D. P. Bartel, "Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation," Science, Vol. 315, no. 5818, pp. 1576-1579, 2007.
51. Y. S. Lee and A. Dutta, "The tumor suppressor microRNA let-7 represses the HMGA2 oncogene," Genes and Development, Vol. 21, no. 9, pp. 1025-1030, 2007.
52. X. Y. He, J. X. Chen, Z. Zhang, C. L. Li, Q. L. Peng, and H. M. Peng, "The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice," Journal of Cancer Research and Clinical Oncology, Vol. 136, no. 7, pp. 1023-1028, 2010.
53. H. K. Hyeon, Y. Kuwano, S. Srikantan, K. L. Eun, J. L. Martindale, and M. Gorospe, "HuR recruits let-7/RISC to repress c-Myc expression," Genes and Development, Vol. 23, no. 15, pp. 1743-1748, 2009.
54. Y.-K. Zhang, W.-Y. Zhu, J.-Y. He et al., "MiRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes," Journal of Cancer Research and Clinical Oncology, Vol. 138, no. 10, pp. 1641-1650, 2012.
55. P. A. Gregory, A. G. Bert, E. L. Paterson et al., "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1," Nature Cell Biology, Vol. 10, no. 5, pp. 593-601, 2008.
56. S. Majid, A. A. Dar, S. Saini et al., "MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer," Cancer, Vol. 116, no. 24, pp. 5637-5649, 2010.
57. L. Xing, N. W. Todd, L. Yu, H. Fang, and F. Jiang, "Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers," Modern Pathology, Vol. 23, no. 8, pp. 1157-1164, 2010.
58. N. Yanaihara, N. Caplen, E. Bowman et al., "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis," Cancer Cell, Vol. 9, no. 3, pp. 189-198, 2006.
59. J. Wei, W. Gao, C.-J. Zhu et al., "Identification of plasma microRNA-21 as a biomarker for early detection and chemosen-sitivity of non-small cell lung cancer," Chinese Journal of Cancer, Vol. 30, no. 6, pp. 407-414, 2011.
60. J. A. Chan, A. M. Krichevsky, and K. S. Kosik, "MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells," Cancer Research, Vol. 65, no. 14, pp. 6029-6033, 2005.
61. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization of squamous cell lung cancers," Nature, Vol. 489, pp. 519-525, 2012.
62. C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim, and G. Getz, "GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers," Genome Biology, Vol. 12, no. 4, article R41, 2011.
63. G. Ciriello, M. L. Miller, B. A. Aksoy, Y. Senbabaoglu, N. Schultz, and C. Sander, "Emerging landscape of oncogenic signatures across human cancers," Nature Genetics, Vol. 45, no. 10, pp. 1127-1133, 2013.
64. D. Lin, D. P. Foster, and L. H. Ungar, "VIF regression: a fast regression algorithm for large data," Journal of the American Statistical Association, Vol. 106, no. 493, pp. 232-247, 2011.
65. T. Huang, L. Liu, Z. Qian, K. Tu, Y. Li, and L. Xie, "Using GeneReg to construct time delay gene regulatory networks," BMC Research Notes, Vol. 3, article 142, 2010.
66. T. Huang, C. Wang, G. Zhang, L. Xie, and Y. Li, "SySAP: a system-level predictor of deleterious single amino acid polymorphisms," Protein and Cell, Vol. 3, no. 1, pp. 38-43, 2012.
67. T. Huang and Y.-D. Cai, "An information-theoretic machine learning approach to expression QTL analysis," PLoS ONE, Vol. 8, no. 6, Article ID e67899, 2013.
68. T. Huang, Z.-S. He, W.-R. Cui et al., "A sequence-based approach for predicting protein disordered regions," Protein and Peptide Letters, Vol. 20, no. 3, pp. 243-248, 2013.
69. Y. Jiang, T. Huang, L. Chen, Y. F. Gao, Y. Cai, and K.-C. Chou, "Signal propagation in protein interaction network during colorectal cancer progression," BioMed Research International, Vol. 2013, Article ID 287019, 9 pages, 2013.
70. T. Huang, W. Cui, Z.-S. He et al., "Functional association between influenza A (H1N1) virus and human," Biochemical and Biophysical Research Communications, Vol. 390, no. 4, pp. 1111-1113, 2009.
71. J. D. Zhang and S. Wiemann, "KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor," Bioinformatics, Vol. 25, no. 11, pp. 1470-1471, 2009.
72. M. Scutari, "Learning Bayesian networks with the bnlearn R Package," Journal of Statistical Software, Vol. 35, no. 3, pp. 1-22, 2010.
73. C. Cillo, M. Cantile, A. Faiella, and E. Boncinelli, "Homeobox genes in normal and malignant cells," Journal of Cellular Physiology, Vol. 188, no. 2, pp. 161-169, 2001.
74. N. Shah and S. Sukumar, "The Hox genes and their roles in oncogenesis," Nature Reviews Cancer, Vol. 10, no. 5, pp. 361-371, 2010.
75. A. Graham, N. Papalopulu, and R. Krumlauf, "The murine and Drosophila homeobox gene complexes have common features of organization and expression," Cell, Vol. 57, no. 3, pp. 367-378, 1989.
76. C. Bach, S. Buhl, D. Mueller, M.-P. García-Cuéllar, E. Maethner, and R. K. Slany, "Leukemogenic transformation by HOXA cluster genes," Blood, Vol. 115, no. 14, pp. 2910-2918, 2010.
77. D. Waltregny, Y. Alami, N. Clausse, J. de Leval, and V. Castronovo, "Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation," Prostate, Vol. 50, no. 3, pp. 162-169, 2002.
78. R. Calvo, J. West, W. Franklin et al., "Altered HOX and WNT7A expression in lung cancer," Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, no. 23, pp. 12776-12781, 2000.
79. M. Abe, J.-I. Hamada, O. Takahashi et al., "Disordered expression of HOX genes in human non-small cell lung cancer," Oncology Reports, Vol. 15, no. 4, pp. 797-802, 2006.
80. Y. J. Miyazaki, J.-I. Hamada, M. Tada et al., "HOXD3 enhances motility and invasiveness through the TGF-β-dependent and -independent pathways in A549 cells," Oncogene, Vol. 21, no. 5, pp. 798-808, 2002.
81. J. Liu, K.-H. Lu, Z.-L. Liu, M. Sun, W. De, and Z.-X. Wang, "MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1," BMC Cancer, Vol. 12, article 519, 2012.
82. F. Xiao, Y. Bai, Z. Chen et al., "Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100," European Journal of Cancer, Vol. 50, no. 8, pp. 1541-1554, 2014.
83. G. Chen, I. A. Umelo, S. Lv et al., "miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells," PLoS ONE, Vol. 8, no. 3, Article ID e60317, 2013.
84. E. V. Stevens, N. Banet, C. Onesto et al., "RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis," Small GTPases, Vol. 2, no. 4, pp. 202-210, 2011.
85. H. Zhen, S. Yang, H. Wu et al., "LyGDI is a promising biomarker for ovarian cancer," International Journal of Gynecological Cancer, Vol. 20, no. 3, pp. 316-322, 2010.
86. H. J. Cho, K. E. Baek, S.-M. Park et al., "RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer," Clinical Cancer Research, Vol. 15, no. 8, pp. 2612-2619, 2009.
87. J. J. Gildea, M. J. Seraj, G. Oxford et al., "RhoGDI2 is an invasion and metastasis suppressor gene in human cancer," Cancer Research, Vol. 62, no. 22, pp. 6418-6423, 2002.
88. H. Niu, H. Li, C. Xu, and P. He, "Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis," Oncology Reports, Vol. 24, no. 2, pp. 465-471, 2010.
89. S. M. Thomas and J. S. Brugge, "Cellular functions regulated by SRC family kinases," Annual Review of Cell and Developmental Biology, Vol. 13, pp. 513-609, 1997.
90. N. Said and D. Theodorescu, "Pathways of metastasis suppression in bladder cancer," Cancer and Metastasis Reviews, Vol. 28, no. 3-4, pp. 327-333, 2009.
91. N. Yamamoto, G. Mammadova, R. X. D. Song, Y. Fukami, and K.-I. Sato, "Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells," Journal of Cell Science, Vol. 119, no. 22, pp. 4623-4633, 2006.
92. M. Curradi, A. Izzo, G. Badaracco, and N. Landsberger, "Molecular mechanisms of gene silencing mediated by DNA methylation," Molecular and Cellular Biology, Vol. 22, no. 9, pp. 3157-3173, 2002.
93. C. P. Goswami and H. Nakshatri, "PROGgene: gene expression based survival analysis web application for multiple cancers," Journal of Clinical Bioinformatics, Vol. 3, no. 1, article 22, 2013.
94. D. P. Harrington and T. R. Fleming, "A class of rank test procedures for censored survival data," Biometrika, Vol. 69, no. 3, pp. 553-566, 1982.
95. P. K. Andersen and R. D. Gill, "Cox's regression model for counting processes: a large sample study," The Annals of Statistics, Vol. 10, no. 4, pp. 1100-1120, 1982.
96. X. Tan, W. Qin, L. Zhang et al., "A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis," Clinical Cancer Research, Vol. 17, no. 21, pp. 6802-6811, 2011.
97. S. Valastyan, F. Reinhardt, N. Benaich et al., "A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis," Cell, Vol. 137, no. 6, pp. 1032-1046, 2009.
98. S. V. Ivanov, C. M. V. Goparaju, P. Lopez et al., "Pro-tumorigenic effects of miR-31 loss in mesothelioma," Journal of Biological Chemistry, Vol. 285, no. 30, pp. 22809-22817, 2010.
99. M. Ruas and G. Peters, "The p16(INK4a)/CDKN2A tumor suppressor and its relatives," Biochimica et Biophysica Acta, Vol. 1378, no. 2, pp. F115-F177, 1998.
100. N. E. Sharpless, "INK4a/ARF: a multifunctional tumor suppressor locus," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 576, no. 1-2, pp. 22-38, 2005.
101. S. Dacic, H. Kothmaier, S. Land et al., "Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas," Virchows Archiv, Vol. 453, no. 6, pp. 627-635, 2008.
102. P. Krimpenfort, A. IJpenberg, J.-Y. Song et al., "p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a," Nature, Vol. 448, no. 7156, pp. 943-946, 2007.
103. T. Nobori, I. Szinai, D. Amox et al., "Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers," Cancer Research, Vol. 53, no. 5, pp. 1098-1101, 1993.
104. Y. Y. Wang, T. Ren, Y. Y. Cai, and X. Y. He, "MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-RAS and HMGA2 gene expression," Cancer Biotherapy and Radiopharmaceuticals, Vol. 28, no. 2, pp. 131-137, 2013.
105. K. Cai, Y. Wan, G. Sun, L. Shi, X. Bao, and Z. Wang, "Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells," Oncology Reports, Vol. 28, no. 6, pp. 2101-2106, 2012.
106. Q. Dong, P. Meng, T. Wang et al., "MicroRNA let-7a inhibits proliferation of human prostate cancer cells In Vitro and In Vivo by targeting E2F2 and CCND2," PLoS ONE, Vol. 5, no. 4, Article ID e10147, 2010.
107. A. Esquela-Kerscher, P. Trang, J. F. Wiggins et al., "The let-7 microRNA reduces tumor growth in mouse models of lung cancer," Cell Cycle, Vol. 7, no. 6, pp. 759-764, 2008.
108. N. Yang, S. Kaur, S. Volinia et al., "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer," Cancer Research, Vol. 68, no. 24, pp. 10307-10314, 2008.
109. L.-N. Wang, W.-W. Chen, J. Zhang et al., "The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells," Asian Journal of Andrology, Vol. 15, no. 6, pp. 753-758, 2013.
110. N. Dahiya, C. A. Sherman-Baust, T.-L. Wang et al., "MicroRNA expression and identification of putative miRNA targets in ovarian cancer," PLoS ONE, Vol. 3, no. 6, Article ID e2436, 2008.
111. Y. Yang, X. Li, Q. Yang et al., "The role of microRNA in human lung squamous cell carcinoma," Cancer Genetics and Cytogenetics, Vol. 200, no. 2, pp. 127-133, 2010.
112. T. R. Jackson, B. G. Kearns, and A. B. Theibert, "Cytohesins and centaurins: mediators of PI 3-kinase-regulated Arf signaling," Trends in Biochemical Sciences, Vol. 25, no. 10, pp. 489-495, 2000.
113. J. Y. Ahn, R. Rong, T. G. Kroll, E. G. van Meir, S. H. Snyder, and K. Ye, "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion," The Journal of Biological Chemistry, Vol. 279, no. 16, pp. 16441-16451, 2004.
114. R. Rong, J.-Y. Ahn, H. Huang et al., "PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis," Nature Neuroscience, Vol. 6, no. 11, pp. 1153-1161, 2003.
115. Q. Qi and K. Ye, "The roles of PIKE in tumorigenesis," Acta Pharmacologica Sinica, Vol. 34, no. 8, pp. 991-997, 2013.
116. C.-B. Chan, X. Liu, M. A. Ensslin et al., "PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development," The EMBO Journal, Vol. 29, no. 5, pp. 956-968, 2010.
117. X. Liu, Y. Hu, C. Hao, S. A. Rempel, and K. Ye, "PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion," Oncogene, Vol. 26, no. 34, pp. 4918-4927, 2007.
118. Y. Cai, J. Wang, R. Li, G. Ayala, M. Ittmann, and M. Liu, "GGAP2/PIKE-A directly activates both the Akt and nuclear factor-κB pathways and promotes prostate cancer progression," Cancer Research, Vol. 69, no. 3, pp. 819-827, 2009.
119. C. B. Knobbe, A. Trampe-Kieslich, and G. Reifenberger, "Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas," Neuropathology and Applied Neurobiology, Vol. 31, no. 5, pp. 486-490, 2005.
120. J.-Y. Ahn, Y. Hu, T. G. Kroll, P. Allard, and K. Ye, "PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt," Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, no. 18, pp. 6993-6998, 2004.
121. V. P. Collins, "Gene amplification in human gliomas," Glia, Vol. 15, no. 3, pp. 289-296, 1995.
122. G. Reifenberger, J. Reifenberger, K. Ichimura, and V. P. Collins, "Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site," Cancer Research, Vol. 55, no. 4, pp. 731-734, 1995.
123. Z. A. Khatib, H. Matsushime, M. Valentine, D. N. Shapiro, C. J. Sherr, and A. T. Look, "Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas," Cancer Research, Vol. 53, no. 22, pp. 5535-5541, 1993.
124. G. Reifenberger, J. Reifenberger, K. Ichimura, P. S. Meltzer, and V. P. Collins, "Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2," Cancer Research, Vol. 54, no. 16, pp. 4299-4303, 1994.
125. G. Reifenberger, K. Ichimura, J. Reifenberger, A. G. Elkahloun, P. S. Meltzer, and V. P. Collins, "Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets," Cancer Research, Vol. 56, no. 22, pp. 5141-5145, 1996.
126. H. Wikman, P. Nymark, A. Väyrynen et al., "CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer," Genes Chromosomes and Cancer, Vol. 42, no. 2, pp. 193-199, 2005.
127. V. Muthusamy, C. Hobbs, C. Nogueira et al., "Amplification of CDK4 and MDM2 in malignant melanoma," Genes Chromosomes and Cancer, Vol. 45, no. 5, pp. 447-454, 2006.
128. H. Kim, W. Huang, X. Jiang, B. Pennicooke, P. J. Park, and M. D. Johnson, "Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship," Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, no. 5, pp. 2183-2188, 2010.
129. S. Ramalingam, K. Pawlish, S. Gadgeel, R. Demers, and G. P. Kalemkerian, "Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database," Journal of Clinical Oncology, Vol. 16, no. 2, pp. 651-657, 1998.
130. Y. E. Miller, "Pathogenesis of lung cancer: 100 Year report," American Journal of Respiratory Cell and Molecular Biology, Vol. 33, no. 3, pp. 216-223, 2005.
131. W. D. Travis, "Pathology of lung cancer," Clinics in Chest Medicine, Vol. 32, no. 4, pp. 669-692, 2011.
132. K. B. Sriram, J. E. Larsen, S. M. Savarimuthu Francis et al., "Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma," PLoS ONE, Vol. 7, no. 2, Article ID e30398, 2012.
133. J. W. Son, K. J. Jeong, W.-S. Jean et al., "Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients," Cancer Letters, Vol. 311, no. 1, pp. 29-37, 2011.
134. I. I. Wistuba, C. Behrens, S. Milchgrub et al., "Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma," Oncogene, Vol. 18, no. 3, pp. 643-650, 1999.
135. I. I. Wistuba, C. Behrens, A. K. Virmani et al., "High resolution chromosome 3p allelotyping of human lung cancer and pre-neoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints," Cancer Research, Vol. 60, no. 7, pp. 1949-1960, 2000.
136. A. Drilon, N. Rekhtman, M. Ladanyi, and P. Paik, "Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy," The Lancet Oncology, Vol. 13, no. 10, pp. e418-e426, 2012.
137. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn Jr. et al., "Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis," Journal of Clinical Oncology, Vol. 21, no. 20, pp. 3798-3807, 2003.
138. S. Dacic, M. Flanagan, K. Cieply et al., "Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma," American Journal of Clinical Pathology, Vol. 125, no. 6, pp. 860-865, 2006.
139. A. J. Ekstrand, N. Sugawa, C. D. James, and V. P. Collins, "Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails," Proceedings of the National Academy of Sciences of the United States of America, Vol. 89, no. 10, pp. 4309-4313, 1992.
140. H. Ji, X. Zhao, Y. Yuza et al., "Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors," Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, no. 20, pp. 7817-7822, 2006.
141. R. S. Heist, L. V. Sequist, and J. A. Engelman, "Genetic changes in squamous cell lung cancer: a review," Journal of Thoracic Oncology, Vol. 7, no. 5, pp. 924-933, 2012.
142. A. E. Karnoub and R. A. Weinberg, "Ras oncogenes: split personalities," Nature Reviews Molecular Cell Biology, Vol. 9, no. 7, pp. 517-531, 2008.
143. Y. Sowa and T. Sakai, "Ras/Raf/MEK/ERK cascade," Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol. 70, supplement 8, pp. 63-66, 2012.
144. J. L. Bos, "Ras oncogenes in human cancer: a review," Cancer Research, Vol. 49, no. 17, pp. 4682-4689, 1989.
145. P. M. K. Westcott and M. D. To, "The genetics and biology of KRAS in lung cancer," Chinese Journal of Cancer, Vol. 32, no. 2, pp. 63-70, 2013.
146. R. Seger and E. G. Krebs, "The MAPK signaling cascade," The FASEB Jour nal, Vol. 9, no. 9, pp. 726-735, 1995.
147. Y. Suzuki, M. Orita, M. Shiraishi, K. Hayashi, and T. Sekiya, "Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products," Oncogene, Vol. 5, no. 7, pp. 1037-1043, 1990.
148. T. Mitsudomi, J. Viallet, J. L. Mulshine, R. I. Linnoila, J. D. Minna, and A. F. Gazdar, "Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines," Oncogene, Vol. 6, no. 8, pp. 1353-1362, 1991.
149. J. A. Engelman, J. Luo, and L. C. Cantley, "The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism," Nature Reviews Genetics, Vol. 7, no. 8, pp. 606-619, 2006.
150. H. Yamamoto, H. Shigematsu, M. Nomura et al., "PIK3CA mutations and copy number gains in human lung cancers," Cancer Research, Vol. 68, no. 17, pp. 6913-6921, 2008.
151. O. Kawano, H. Sasaki, K. Okuda et al., "PIK3CA gene amplification in Japanese non-small cell lung cancer," Lung Cancer, Vol. 58, no. 1, pp. 159-160, 2007.
152. Y. Samuels, Z. Wang, A. Bardelli et al., "High frequency of mutations of the PIK3CA gene in human cancers," Science, Vol. 304, article 554, 2004.
153. O. Kawano, H. Sasaki, K. Endo et al., "PIK3CA mutation status in Japanese lung cancer patients," Lung Cancer, Vol. 54, no. 2, pp. 209-215, 2006.
154. I. Vivanco and C. L. Sawyers, "The phosphatidylinositol 3-kinase-AKT pathway in human cancer," Nature Reviews Cancer, Vol. 2, no. 7, pp. 489-501, 2002.
155. D. Malanga, M. Scrima, C. de Marco et al., "Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung," Cell Cycle, Vol. 7, no. 5, pp. 665-669, 2008.
156. J. Weiss, M. L. Sos, D. Seidel et al., "Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer," Science Translational Medicine, Vol. 2, no. 62, Article ID 62ra93, 2010.
157. I. Mason, "Initiation to end point: the multiple roles of fibroblast growth factors in neural development," Nature Reviews Neuroscience, Vol. 8, no. 8, pp. 583-596, 2007.
158. R. Dziadziuszko, D. T. Merrick, S. E. Witta et al., "Insulinlike growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression," Journal of Clinical Oncology, Vol. 28, no. 13, pp. 2174-2180, 2010.
159. F. Cappuzzo, G. Tallini, G. Finocchiaro et al., "Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients," Annals of Oncology, Vol. 21, no. 3, pp. 562-567, 2009.
160. A. Gualberto, M. Dolled-Filhart, M. Gustavson et al., "Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition," Clinical Cancer Research, Vol. 16, no. 18, pp. 4654-4665, 2010.
161. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization of squamous cell lung cancers," Nature, Vol. 489, no. 7417, pp. 519-525, 2012.
162. E. R. Zabarovsky, M. I. Lerman, and J. D. Minna, "Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers," Oncogene, Vol. 21, no. 45, pp. 6915-6935, 2002.
163. M. Rooney, S. Devarakonda, and R. Govindana, "Genomics of squamous cell lung cancer," Oncologist, Vol. 18, no. 6, pp. 707-716, 2013.
164. C. H. de Moor, H. Meijer, and S. Lissenden, "Mechanisms of translational control by the 3' UTR in development and differentiation," Seminars in Cell and Developmental Biology, Vol. 16, no. 1, pp. 49-58, 2005.
165. E. C. Lai, "Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation," Nature Genetics, Vol. 30, no. 4, pp. 363-364, 2002.
166. H. Robins and W. H. Press, "Human microRNAs target a functionally distinct population of genes with AT-rich 3' UTRs," Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, no. 43, pp. 15557-15562, 2005.
167. A. Stark, J. Brennecke, N. Bushati, R. B. Russell, and S. M. Cohen, "Animal microRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution," Cell, Vol. 123, no. 6, pp. 1133-1146, 2005.
168. M. Sun, L. D. Hurst, G. G. Carmichael, and J. Chen, "Evidence for a preferential targeting of 3'-UTRs by cis-encoded natural antisense transcripts," Nucleic Acids Research, Vol. 33, no. 17, pp. 5533-5543, 2005.
169. W. C. S. Cho, "MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy," International Journal of Biochemistry and Cell Biology, Vol. 42, no. 8, pp. 1273-1281, 2010.
170. L. He, X. He, S. W. Lowe, and G. J. Hannon, "MicroRNAs join the p53 network - another piece in the tumour-suppression puzzle," Nature Reviews Cancer, Vol. 7, no. 11, pp. 819-822, 2007.
171. W. C. S. Cho, "OncomiRs: the discovery and progress of microRNAs in cancers," Molecular Cancer, Vol. 6, article 60, 2007.
172. H.-W. Hwang and J. T. Mendell, "MicroRNAs in cell proliferation, cell death, and tumorigenesis," British Journal of Cancer, Vol. 94, no. 6, pp. 776-780, 2006.
173. A. Esquela-Kerscher and F. J. Slack, "Oncomirs - microRNAs with a role in cancer," Nature Reviews Cancer, Vol. 6, no. 4, pp. 259-269, 2006.
174. E. C. Lai, P. Tomancak, R. W. Williams, and G. M. Rubin, "Computational identification of Drosophila microRNA genes," Genome Biology, Vol. 4, no. 7, article R42, 2003.
175. B. J. Reinhart, F. J. Slack, M. Basson et al., "The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans," Nature, Vol. 403, no. 6772, pp. 901-906, 2000.
176. J. Takamizawa, H. Konishi, K. Yanagisawa et al., "Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival," Cancer Research, Vol. 64, no. 11, pp. 3753-3756, 2004.
177. S. M. Johnson, H. Grosshans, J. Shingara et al., "RAS is regulated by the let-7 microRNA family," Cell, Vol. 120, no. 5, pp. 635-647, 2005.
178. C. Mayr, M. T. Hemann, and D. P. Bartel, "Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation," Science, Vol. 315, no. 5818, pp. 1576-1579, 2007.
179. Y. S. Lee and A. Dutta, "The tumor suppressor microRNA let-7 represses the HMGA2 oncogene," Genes and Development, Vol. 21, no. 9, pp. 1025-1030, 2007.
180. X. Y. He, J. X. Chen, Z. Zhang, C. L. Li, Q. L. Peng, and H. M. Peng, "The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice," Journal of Cancer Research and Clinical Oncology, Vol. 136, no. 7, pp. 1023-1028, 2010.
181. H. K. Hyeon, Y. Kuwano, S. Srikantan, K. L. Eun, J. L. Martindale, and M. Gorospe, "HuR recruits let-7/RISC to repress c-Myc expression," Genes and Development, Vol. 23, no. 15, pp. 1743-1748, 2009.
182. Y.-K. Zhang, W.-Y. Zhu, J.-Y. He et al., "MiRNAs expression profiling to distinguish lung squamous-cell carcinoma from adenocarcinoma subtypes," Journal of Cancer Research and Clinical Oncology, Vol. 138, no. 10, pp. 1641-1650, 2012.
183. P. A. Gregory, A. G. Bert, E. L. Paterson et al., "The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1," Nature Cell Biology, Vol. 10, no. 5, pp. 593-601, 2008.
184. S. Majid, A. A. Dar, S. Saini et al., "MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer," Cancer, Vol. 116, no. 24, pp. 5637-5649, 2010.
185. L. Xing, N. W. Todd, L. Yu, H. Fang, and F. Jiang, "Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers," Modern Pathology, Vol. 23, no. 8, pp. 1157-1164, 2010.
186. N. Yanaihara, N. Caplen, E. Bowman et al., "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis," Cancer Cell, Vol. 9, no. 3, pp. 189-198, 2006.
187. J. Wei, W. Gao, C.-J. Zhu et al., "Identification of plasma microRNA-21 as a biomarker for early detection and chemosen-sitivity of non-small cell lung cancer," Chinese Journal of Cancer, Vol. 30, no. 6, pp. 407-414, 2011.
188. J. A. Chan, A. M. Krichevsky, and K. S. Kosik, "MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells," Cancer Research, Vol. 65, no. 14, pp. 6029-6033, 2005.
189. Cancer Genome Atlas Research Network, "Comprehensive genomic characterization of squamous cell lung cancers," Nature, Vol. 489, pp. 519-525, 2012.
190. C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim, and G. Getz, "GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers," Genome Biology, Vol. 12, no. 4, article R41, 2011.
191. G. Ciriello, M. L. Miller, B. A. Aksoy, Y. Senbabaoglu, N. Schultz, and C. Sander, "Emerging landscape of oncogenic signatures across human cancers," Nature Genetics, Vol. 45, no. 10, pp. 1127-1133, 2013.
192. D. Lin, D. P. Foster, and L. H. Ungar, "VIF regression: a fast regression algorithm for large data," Journal of the American Statistical Association, Vol. 106, no. 493, pp. 232-247, 2011.
193. T. Huang, L. Liu, Z. Qian, K. Tu, Y. Li, and L. Xie, "Using GeneReg to construct time delay gene regulatory networks," BMC Research Notes, Vol. 3, article 142, 2010.
194. T. Huang, C. Wang, G. Zhang, L. Xie, and Y. Li, "SySAP: a system-level predictor of deleterious single amino acid polymorphisms," Protein and Cell, Vol. 3, no. 1, pp. 38-43, 2012.
195. T. Huang and Y.-D. Cai, "An information-theoretic machine learning approach to expression QTL analysis," PLoS ONE, Vol. 8, no. 6, Article ID e67899, 2013.
196. T. Huang, Z.-S. He, W.-R. Cui et al., "A sequence-based approach for predicting protein disordered regions," Protein and Peptide Letters, Vol. 20, no. 3, pp. 243-248, 2013.
197. Y. Jiang, T. Huang, L. Chen, Y. F. Gao, Y. Cai, and K.-C. Chou, "Signal propagation in protein interaction network during colorectal cancer progression," BioMed Research International, Vol. 2013, Article ID 287019, 9 pages, 2013.
198. T. Huang, W. Cui, Z.-S. He et al., "Functional association between influenza A (H1N1) virus and human," Biochemical and Biophysical Research Communications, Vol. 390, no. 4, pp. 1111-1113, 2009.
199. J. D. Zhang and S. Wiemann, "KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor," Bioinformatics, Vol. 25, no. 11, pp. 1470-1471, 2009.
200. M. Scutari, "Learning Bayesian networks with the bnlearn R Package," Journal of Statistical Software, Vol. 35, no. 3, pp. 1-22, 2010.
201. C. Cillo, M. Cantile, A. Faiella, and E. Boncinelli, "Homeobox genes in normal and malignant cells," Journal of Cellular Physiology, Vol. 188, no. 2, pp. 161-169, 2001.
202. N. Shah and S. Sukumar, "The Hox genes and their roles in oncogenesis," Nature Reviews Cancer, Vol. 10, no. 5, pp. 361-371, 2010.
203. A. Graham, N. Papalopulu, and R. Krumlauf, "The murine and Drosophila homeobox gene complexes have common features of organization and expression," Cell, Vol. 57, no. 3, pp. 367-378, 1989.
204. C. Bach, S. Buhl, D. Mueller, M.-P. García-Cuéllar, E. Maethner, and R. K. Slany, "Leukemogenic transformation by HOXA cluster genes," Blood, Vol. 115, no. 14, pp. 2910-2918, 2010.
205. D. Waltregny, Y. Alami, N. Clausse, J. de Leval, and V. Castronovo, "Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation," Prostate, Vol. 50, no. 3, pp. 162-169, 2002.
206. R. Calvo, J. West, W. Franklin et al., "Altered HOX and WNT7A expression in lung cancer," Proceedings of the National Academy of Sciences of the United States of America, Vol. 97, no. 23, pp. 12776-12781, 2000.
207. M. Abe, J.-I. Hamada, O. Takahashi et al., "Disordered expression of HOX genes in human non-small cell lung cancer," Oncology Reports, Vol. 15, no. 4, pp. 797-802, 2006.
208. Y. J. Miyazaki, J.-I. Hamada, M. Tada et al., "HOXD3 enhances motility and invasiveness through the TGF-β-dependent and -independent pathways in A549 cells," Oncogene, Vol. 21, no. 5, pp. 798-808, 2002.
209. J. Liu, K.-H. Lu, Z.-L. Liu, M. Sun, W. De, and Z.-X. Wang, "MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1," BMC Cancer, Vol. 12, article 519, 2012.
210. F. Xiao, Y. Bai, Z. Chen et al., "Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100," European Journal of Cancer, Vol. 50, no. 8, pp. 1541-1554, 2014.
211. G. Chen, I. A. Umelo, S. Lv et al., "miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells," PLoS ONE, Vol. 8, no. 3, Article ID e60317, 2013.
212. E. V. Stevens, N. Banet, C. Onesto et al., "RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis," Small GTPases, Vol. 2, no. 4, pp. 202-210, 2011.
213. H. Zhen, S. Yang, H. Wu et al., "LyGDI is a promising biomarker for ovarian cancer," International Journal of Gynecological Cancer, Vol. 20, no. 3, pp. 316-322, 2010.
214. H. J. Cho, K. E. Baek, S.-M. Park et al., "RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer," Clinical Cancer Research, Vol. 15, no. 8, pp. 2612-2619, 2009.
215. J. J. Gildea, M. J. Seraj, G. Oxford et al., "RhoGDI2 is an invasion and metastasis suppressor gene in human cancer," Cancer Research, Vol. 62, no. 22, pp. 6418-6423, 2002.
216. H. Niu, H. Li, C. Xu, and P. He, "Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis," Oncology Reports, Vol. 24, no. 2, pp. 465-471, 2010.
217. S. M. Thomas and J. S. Brugge, "Cellular functions regulated by SRC family kinases," Annual Review of Cell and Developmental Biology, Vol. 13, pp. 513-609, 1997.
218. N. Said and D. Theodorescu, "Pathways of metastasis suppression in bladder cancer," Cancer and Metastasis Reviews, Vol. 28, no. 3-4, pp. 327-333, 2009.
219. N. Yamamoto, G. Mammadova, R. X. D. Song, Y. Fukami, and K.-I. Sato, "Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells," Journal of Cell Science, Vol. 119, no. 22, pp. 4623-4633, 2006.
220. M. Curradi, A. Izzo, G. Badaracco, and N. Landsberger, "Molecular mechanisms of gene silencing mediated by DNA methylation," Molecular and Cellular Biology, Vol. 22, no. 9, pp. 3157-3173, 2002.
221. C. P. Goswami and H. Nakshatri, "PROGgene: gene expression based survival analysis web application for multiple cancers," Journal of Clinical Bioinformatics, Vol. 3, no. 1, article 22, 2013.
222. D. P. Harrington and T. R. Fleming, "A class of rank test procedures for censored survival data," Biometrika, Vol. 69, no. 3, pp. 553-566, 1982.
223. P. K. Andersen and R. D. Gill, "Cox's regression model for counting processes: a large sample study," The Annals of Statistics, Vol. 10, no. 4, pp. 1100-1120, 1982.
224. X. Tan, W. Qin, L. Zhang et al., "A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis," Clinical Cancer Research, Vol. 17, no. 21, pp. 6802-6811, 2011.
225. S. Valastyan, F. Reinhardt, N. Benaich et al., "A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis," Cell, Vol. 137, no. 6, pp. 1032-1046, 2009.
226. S. V. Ivanov, C. M. V. Goparaju, P. Lopez et al., "Pro-tumorigenic effects of miR-31 loss in mesothelioma," Journal of Biological Chemistry, Vol. 285, no. 30, pp. 22809-22817, 2010.
227. M. Ruas and G. Peters, "The p16(INK4a)/CDKN2A tumor suppressor and its relatives," Biochimica et Biophysica Acta, Vol. 1378, no. 2, pp. F115-F177, 1998.
228. N. E. Sharpless, "INK4a/ARF: a multifunctional tumor suppressor locus," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 576, no. 1-2, pp. 22-38, 2005.
229. S. Dacic, H. Kothmaier, S. Land et al., "Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas," Virchows Archiv, Vol. 453, no. 6, pp. 627-635, 2008.
230. P. Krimpenfort, A. IJpenberg, J.-Y. Song et al., "p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a," Nature, Vol. 448, no. 7156, pp. 943-946, 2007.
231. T. Nobori, I. Szinai, D. Amox et al., "Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers," Cancer Research, Vol. 53, no. 5, pp. 1098-1101, 1993.
232. Y. Y. Wang, T. Ren, Y. Y. Cai, and X. Y. He, "MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-RAS and HMGA2 gene expression," Cancer Biotherapy and Radiopharmaceuticals, Vol. 28, no. 2, pp. 131-137, 2013.
233. K. Cai, Y. Wan, G. Sun, L. Shi, X. Bao, and Z. Wang, "Let-7a inhibits proliferation and induces apoptosis by targeting EZH2 in nasopharyngeal carcinoma cells," Oncology Reports, Vol. 28, no. 6, pp. 2101-2106, 2012.
234. Q. Dong, P. Meng, T. Wang et al., "MicroRNA let-7a inhibits proliferation of human prostate cancer cells In Vitro and In Vivo by targeting E2F2 and CCND2," PLoS ONE, Vol. 5, no. 4, Article ID e10147, 2010.
235. A. Esquela-Kerscher, P. Trang, J. F. Wiggins et al., "The let-7 microRNA reduces tumor growth in mouse models of lung cancer," Cell Cycle, Vol. 7, no. 6, pp. 759-764, 2008.
236. N. Yang, S. Kaur, S. Volinia et al., "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer," Cancer Research, Vol. 68, no. 24, pp. 10307-10314, 2008.
237. L.-N. Wang, W.-W. Chen, J. Zhang et al., "The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells," Asian Journal of Andrology, Vol. 15, no. 6, pp. 753-758, 2013.
238. N. Dahiya, C. A. Sherman-Baust, T.-L. Wang et al., "MicroRNA expression and identification of putative miRNA targets in ovarian cancer," PLoS ONE, Vol. 3, no. 6, Article ID e2436, 2008.
239. Y. Yang, X. Li, Q. Yang et al., "The role of microRNA in human lung squamous cell carcinoma," Cancer Genetics and Cytogenetics, Vol. 200, no. 2, pp. 127-133, 2010.
240. T. R. Jackson, B. G. Kearns, and A. B. Theibert, "Cytohesins and centaurins: mediators of PI 3-kinase-regulated Arf signaling," Trends in Biochemical Sciences, Vol. 25, no. 10, pp. 489-495, 2000.
241. J. Y. Ahn, R. Rong, T. G. Kroll, E. G. van Meir, S. H. Snyder, and K. Ye, "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion," The Journal of Biological Chemistry, Vol. 279, no. 16, pp. 16441-16451, 2004.
242. R. Rong, J.-Y. Ahn, H. Huang et al., "PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis," Nature Neuroscience, Vol. 6, no. 11, pp. 1153-1161, 2003.
243. Q. Qi and K. Ye, "The roles of PIKE in tumorigenesis," Acta Pharmacologica Sinica, Vol. 34, no. 8, pp. 991-997, 2013.
244. C.-B. Chan, X. Liu, M. A. Ensslin et al., "PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development," The EMBO Journal, Vol. 29, no. 5, pp. 956-968, 2010.
245. X. Liu, Y. Hu, C. Hao, S. A. Rempel, and K. Ye, "PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion," Oncogene, Vol. 26, no. 34, pp. 4918-4927, 2007.
246. Y. Cai, J. Wang, R. Li, G. Ayala, M. Ittmann, and M. Liu, "GGAP2/PIKE-A directly activates both the Akt and nuclear factor-κB pathways and promotes prostate cancer progression," Cancer Research, Vol. 69, no. 3, pp. 819-827, 2009.
247. C. B. Knobbe, A. Trampe-Kieslich, and G. Reifenberger, "Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas," Neuropathology and Applied Neurobiology, Vol. 31, no. 5, pp. 486-490, 2005.
248. J.-Y. Ahn, Y. Hu, T. G. Kroll, P. Allard, and K. Ye, "PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt," Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, no. 18, pp. 6993-6998, 2004.
249. V. P. Collins, "Gene amplification in human gliomas," Glia, Vol. 15, no. 3, pp. 289-296, 1995.
250. G. Reifenberger, J. Reifenberger, K. Ichimura, and V. P. Collins, "Amplification at 12q13-14 in human malignant gliomas is frequently accompanied by loss of heterozygosity at loci proximal and distal to the amplification site," Cancer Research, Vol. 55, no. 4, pp. 731-734, 1995.
251. Z. A. Khatib, H. Matsushime, M. Valentine, D. N. Shapiro, C. J. Sherr, and A. T. Look, "Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas," Cancer Research, Vol. 53, no. 22, pp. 5535-5541, 1993.
252. G. Reifenberger, J. Reifenberger, K. Ichimura, P. S. Meltzer, and V. P. Collins, "Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2," Cancer Research, Vol. 54, no. 16, pp. 4299-4303, 1994.
253. G. Reifenberger, K. Ichimura, J. Reifenberger, A. G. Elkahloun, P. S. Meltzer, and V. P. Collins, "Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets," Cancer Research, Vol. 56, no. 22, pp. 5141-5145, 1996.
254. H. Wikman, P. Nymark, A. Väyrynen et al., "CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer," Genes Chromosomes and Cancer, Vol. 42, no. 2, pp. 193-199, 2005.
255. V. Muthusamy, C. Hobbs, C. Nogueira et al., "Amplification of CDK4 and MDM2 in malignant melanoma," Genes Chromosomes and Cancer, Vol. 45, no. 5, pp. 447-454, 2006.
256. H. Kim, W. Huang, X. Jiang, B. Pennicooke, P. J. Park, and M. D. Johnson, "Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship," Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, no. 5, pp. 2183-2188, 2010.